Trials & Tribulations What NHS-Galleri taught us—and what it didn’t June 18, 2026Vol.52 No.24By Scott D. Ramsey and Ruth Etzioni
Trials & Tribulations The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies June 18, 2026Vol.52 No.24By Bryan Bassig, Catherine R. Marinac, David M. Routman, Elizabeth K. O'Donnell, Jennifer Keating Litton, Karthik V. Giridhar, Kennedy Ng Yao Yi, Kurt Giles, Nima Nabavizadeh, Ora K. Gordon, Rebecca Kaltman and Shawn Kothari
FreeTrials & Tribulations Lessons from the AIDS Quilt: what the cancer world can learn from AIDS advocacy June 12, 2026Vol.52 No.23By Peter F. Garrett
Trials & Tribulations The story of daraxonrasib is the ultimate hero’s journeyA narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe June 05, 2026Vol.52 No.22By W. Kimryn Rathmell
Trials & Tribulations As rural cancer disparities persist, aligning policy with care delivery models can close the gap May 29, 2026Vol.52 No.21By Matthew L. Anderson
Trials & Tribulations Protecting the cure: Why the future of radiation oncology must be precision-guided April 10, 2026Vol.52 No.14By J. Isabelle Choi
FreeTrials & Tribulations Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients March 27, 2026Vol.52 No.12By W. Kimryn Rathmell
Trials & Tribulations In the era of immunotherapy, response rate alone fails to predict true patient benefitRegulators must adapt March 27, 2026Vol.52 No.12By Richard M. Goldberg
Trials & Tribulations Why infection and immunity matter for Florida’s cancer patients February 13, 2026Vol.52 No.06By Eduardo Sotomayor
FreeTrials & Tribulations Supportive cancer care is the smart investment our leaders in Washington can’t afford to ignore January 30, 2026Vol.52 No.04By Les Biller
